Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Core Insights - Teva Pharmaceutical Industries Ltd. plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting in San Diego, California, from September 17 to 21, 2025 [1] - A conference call for analysts and investors will be held on September 22, 2025, at 11:00 a.m. ET to discuss the trial data [1] Company Overview - Teva is a leading innovative biopharmaceutical company with a strong generics business, committed to addressing patients' needs for over 120 years [3] - The company focuses on innovation in neuroscience and immunology, as well as providing complex generic medicines, biosimilars, and pharmacy brands globally [3]